Reuters logo
in a month
BRIEF-Portola Pharmaceuticals interim data from a phase 2A study evaluating Cerdulatinib
June 15, 2017 / 1:05 PM / in a month

BRIEF-Portola Pharmaceuticals interim data from a phase 2A study evaluating Cerdulatinib

1 Min Read

June 15 (Reuters) - Portola Pharmaceuticals Inc

* Interim data from a phase 2A study evaluating Cerdulatinib in patients with relapsed/refractory B-cell malignancies

* Interim results demonstrated evidence of clinical activity in patients with relapsed/refractory (R/R) B-cell malignancies

* A complete response was seen in first R/R peripheral T cell lymphoma (PTCL) patient evaluated in study

* Results also showed that Cerdulatinib was generally well-tolerated in the heavily pre-treated patients

* Anticipate an update on ongoing study on Cerdulatinib and a decision regarding future development by end of 2017

* Reduction in doseage resulted in an improved PK and safety profile without compromising clinical activity Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below